{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:00:40Z","timestamp":1784718040927,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Clostridioides difficile<\/jats:italic>\n                    infection (CDI) remains a leading cause of antibiotic-associated diarrhoea, with high recurrence rates and limited treatment options that preserve gut microbiota. Current treatments, including vancomycin, further disrupt the already compromised gut microbiota, often prolonging dysbiosis and increasing the risk of colonization by resistant pathogens. This study demonstrates that argyrin B exhibits potent activity against\n                    <jats:italic>C. difficile<\/jats:italic>\n                    in vitro and significantly reduces bacterial burden in a mouse model of infection. Argyrin B displayed a narrow antimicrobial spectrum, suggesting that commensal gut bacteria are hardly affected, and may allow for a faster restoration of the antibiotic pre-damaged gut microbiota. The compound exhibited a pharmacokinetic profile characterized by low systemic absorption and elevated colonic concentrations, representing favourable characteristics. The compound acts through a novel mechanism by targeting elongation factor G, distinct from existing therapies, and resistance emerged at low frequency via point mutations in the target gene. These features suggest that argyrin B may offer a novel and well-tolerated therapeutic approach for CDI, with potential to support microbiota preservation, which may contribute to reduced recurrence risk.\n                  <\/jats:p>","DOI":"10.1038\/s44259-026-00248-x","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:15:33Z","timestamp":1784153733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Argyrin B exhibits potent therapeutic efficacy in a Clostridioides difficile-infection mouse model while preserving microbiota functionality"],"prefix":"10.1038","volume":"4","author":[{"given":"Sari","family":"Rasheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mohamed Mostafa Abdrabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lechleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domen","family":"Pogorevc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabryna","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"von M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guntram","family":"A. Grassl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"248_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","volume":"38","author":"J Czepiel","year":"2019","unstructured":"Czepiel, J. et al. Clostridium difficile infection: review. Eur. J. Clin. Microbiol Infect. Dis. 38, 1211\u20131221 (2019).","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"248_CR2","doi-asserted-by":"publisher","unstructured":"Vendrik K. E. W. et al. Comparison of trends in Clostridioides difficile infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: a retrospective sentinel surveillance study. Lancet Reg. Health\u2014Europe 19, https:\/\/doi.org\/10.1016\/j.lanepe.2022.100424 (2022).","DOI":"10.1016\/j.lanepe.2022.100424"},{"key":"248_CR3","doi-asserted-by":"crossref","unstructured":"Balsells, E. et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J. Glob. Health 9, 010407 (2019).","DOI":"10.7189\/jogh.09.010407"},{"key":"248_CR4","doi-asserted-by":"publisher","unstructured":"Mougiou D., Gioula G., Skoura L., Anastassopoulou C. & Kachrimanidou M. Insights into the interaction between Clostridioides difficile and the gut microbiome. J. Personal. Med. 15, https:\/\/doi.org\/10.3390\/jpm15030094 (2025).","DOI":"10.3390\/jpm15030094"},{"key":"248_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-025-00687-3","volume":"17","author":"A Mahnic","year":"2025","unstructured":"Mahnic, A. et al. Clostridioides difficile concentration-dependant alterations in gut microbiota of asymptomatic infants. Gut Pathog. 17, 17 (2025).","journal-title":"Gut Pathog."},{"key":"248_CR6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cmi.2019.10.023","volume":"26","author":"SC Lim","year":"2020","unstructured":"Lim, S. C., Knight, D. R. & Riley, T. V. Clostridium difficile and One Health. Clin. Microbiol. Infect. 26, 857\u2013863 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"248_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1053\/j.gastro.2014.01.059","volume":"146","author":"RA Britton","year":"2014","unstructured":"Britton, R. A. & Young, V. B. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146, 1547\u20131553 (2014). The Gut Microbiome in Health and Disease.","journal-title":"Gastroenterology"},{"key":"248_CR8","doi-asserted-by":"crossref","unstructured":"Kachrimanidou M. & Tsintarakis E. Insights into the role of human gut microbiota in Clostridioides difficile infection. Microorganisms8, 2 (2020).","DOI":"10.3390\/microorganisms8020200"},{"key":"248_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/pathogens13080646","volume":"13","author":"P Spigaglia","year":"2024","unstructured":"Spigaglia, P. Clostridioides difficile and gut microbiota: from colonization to infection and treatment. Pathogens 13, 8 (2024).","journal-title":"Pathogens"},{"key":"248_CR10","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","volume":"73","author":"S Johnson","year":"2021","unstructured":"Johnson, S. et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin. Infect. Dis. 73, e1029\u2013e1044 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"248_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie, T. J. et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N. Engl. J. Med. 364, 422\u2013431 (2011).","journal-title":"N. Engl. J. Med."},{"key":"248_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely, O. A. et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomized controlled trial. Lancet Infect. Dis. 12, 281\u2013289 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"248_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01206-24","volume":"68","author":"TM Le","year":"2024","unstructured":"Le, T. M. et al. Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites. Antimicrob. Agents Chemother. 68, e01206-24 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"248_CR14","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s40265-016-0673-1","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham, A. Bezlotoxumab: first global approval. Drugs 76, 1793\u20131798 (2016).","journal-title":"Drugs"},{"key":"248_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/MOG.0b013e32835a4b3e","volume":"29","author":"OC Aroniadis","year":"2013","unstructured":"Aroniadis, O. C. & Brandt, L. J. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol. 29, 79 (2013).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"248_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/cid\/ciaf028","volume":"80","author":"SN Redmond","year":"2025","unstructured":"Redmond, S. N. et al. Emergence and spread of clostridioides difficile isolates with reduced fidaxomicin susceptibility in an acute care hospital. Clin. Infect. Dis. 80, 984\u2013991 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"248_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/jac\/dky375","volume":"74","author":"J Schwanbeck","year":"2019","unstructured":"Schwanbeck, J. et al. Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB. J. Antimicrob. Chemother. 74, 6\u201310 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"248_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery, A. F. et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology 166, 409\u2013434 (2024).","journal-title":"Gastroenterology"},{"key":"248_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.7861\/clinmedicine.18-3-237","volume":"18","author":"BH Mullish","year":"2018","unstructured":"Mullish, B. H. & Williams, H. R. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin. Med. (Lond.) 18, 237\u2013241 (2018).","journal-title":"Clin. Med. (Lond.)"},{"key":"248_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000016879","volume":"16","author":"LV McFarland","year":"1998","unstructured":"McFarland, L. V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. 16, 292\u2013307 (1998).","journal-title":"Dig. Dis."},{"key":"248_CR21","doi-asserted-by":"publisher","unstructured":"Sch\u00e4ffler H., Breitr\u00fcck A. Clostridium difficile\u2014from colonization to infection. Front. Microbiol. 9, https:\/\/doi.org\/10.3389\/fmicb.2018.00646 (2018).","DOI":"10.3389\/fmicb.2018.00646"},{"key":"248_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nrmicro2164","volume":"7","author":"M Rupnik","year":"2009","unstructured":"Rupnik, M., Wilcox, M. H. & Gerding, D. N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7, 526\u2013536 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"248_CR23","unstructured":"World Health Organization (WHO). Antibacterial agents in clinical and preclinical development: an overview and analysis. https:\/\/www.who.int\/publications\/i\/item\/9789240113091 (2025)."},{"key":"248_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7164\/antibiotics.49.145","volume":"49","author":"E Selva","year":"1996","unstructured":"Selva, E. et al. Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. I. Taxonomy, isolation and characterization. J. Antibiot. 49, 145\u2013149 (1996).","journal-title":"J. Antibiot."},{"key":"248_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.7164\/antibiotics.49.150","volume":"49","author":"P Ferrari","year":"1996","unstructured":"Ferrari, P. et al. Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. II. Structure elucidation. J. Antibiot. 49, 150\u2013154 (1996).","journal-title":"J. Antibiot."},{"key":"248_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7164\/antibiotics.55.543","volume":"55","author":"F Sasse","year":"2002","unstructured":"Sasse, F. et al. Argyrins, immunosuppressive cyclic peptides from Myxobacteria I. Production, isolation, physico-chemical and biological properties. J. Antibiot. 55, 543\u2013551 (2002).","journal-title":"J. Antibiot."},{"key":"248_CR27","doi-asserted-by":"publisher","unstructured":"Jones, A. K. et al. Determinants of antibacterial spectrum and resistance potential of the elongation factor G inhibitor Argyrin B in key Gram-negative pathogens. Antimicrob. Agents Chemother.61, https:\/\/doi.org\/10.1128\/aac.02400-16 (2017).","DOI":"10.1128\/aac.02400-16"},{"key":"248_CR28","doi-asserted-by":"publisher","first-page":"e42657","DOI":"10.1371\/journal.pone.0042657","volume":"7","author":"B Nyfeler","year":"2012","unstructured":"Nyfeler, B. et al. Identification of elongation factor G as the conserved cellular target of argyrin B. PLoS ONE 7, e42657 (2012).","journal-title":"PLoS ONE"},{"key":"248_CR29","doi-asserted-by":"publisher","first-page":"30257","DOI":"10.1074\/jbc.M112.378521","volume":"287","author":"RK Koripella","year":"2012","unstructured":"Koripella, R. K. et al. Mechanism of elongation factor-G-mediated fusidic acid resistance and fitness compensation in Staphylococcus aureus. J. Biol. Chem. 287, 30257\u201330267 (2012).","journal-title":"J. Biol. Chem."},{"key":"248_CR30","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cbic.201200479","volume":"13","author":"P Bielecki","year":"2012","unstructured":"Bielecki, P. et al. Mutation in elongation factor G confers resistance to the antibiotic argyrin in the opportunistic pathogen Pseudomonas aeruginosa. ChemBioChem 13, 2339\u20132345 (2012).","journal-title":"ChemBioChem"},{"key":"248_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114214119","volume":"119","author":"M Wieland","year":"2022","unstructured":"Wieland, M. et al. The cyclic octapeptide antibiotic argyrin B inhibits translation by trapping EF-G on the ribosome during translocation. Proc. Natl. Acad. Sci. USA 119, e2114214119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"248_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1751-7915.13959","volume":"15","author":"D Pogorevc","year":"2022","unstructured":"Pogorevc, D. & M\u00fcller, R. Biotechnological production optimization of argyrins\u2014a potent immunomodulatory natural product class. Microb. Biotechnol. 15, 353\u2013369 (2022).","journal-title":"Microb. Biotechnol."},{"key":"248_CR33","unstructured":"German center for Infection Research. Compound Resources and Medicinal Chemistry. https:\/\/www.dzif.de\/en\/compound-resources-and-medicinal-chemistry"},{"key":"248_CR34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.chom.2023.04.003","volume":"31","author":"A Bublitz","year":"2023","unstructured":"Bublitz, A. et al. The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection. Cell Host Microbe 31, 734\u2013750.e8 (2023).","journal-title":"Cell Host Microbe"},{"key":"248_CR35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1039\/D2NP00012A","volume":"39","author":"AK Krome","year":"2022","unstructured":"Krome, A. K. et al. Corallopyronin A: antimicrobial discovery to preclinical development. Nat. Prod. Rep. 39, 1705\u20131720 (2022).","journal-title":"Nat. Prod. Rep."},{"key":"248_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.7164\/antibiotics.48.26","volume":"48","author":"H Irschik","year":"1995","unstructured":"Irschik, H., Schummer, D., Gerth, K., H\u00f6fle, G. & Reichenbach, H. The tartrolons, new boron-containing antibiotics from a myxobacterium, Sorangium cellulosum. J. Antibiot. (Tokyo) 48, 26\u201330 (1995).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"248_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.7164\/antibiotics.53.879","volume":"53","author":"F Sasse","year":"2000","unstructured":"Sasse, F., Steinmetz, H., Heil, J., H\u00f6fle, G. & Reichenbach, H. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. production, isolation, physico-chemical and biological properties. J. Antibiot. (Tokyo) 53, 879\u2013885 (2000).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"248_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7164\/antibiotics.40.7","volume":"40","author":"H Irschik","year":"1987","unstructured":"Irschik, H., Jansen, R., Gerth, K., H\u00f6fle, G. & Reichenbach, H. The sorangicins, novel and powerful inhibitors of eubacterial RNA polymerase isolated from myxobacteria. J. Antibiot. 40, 7\u201313 (1987).","journal-title":"J. Antibiot."},{"key":"248_CR39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/sj.emboj.7600499","volume":"24","author":"EA Campbell","year":"2005","unstructured":"Campbell, E. A. et al. Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase. EMBO J. 24, 674\u2013682 (2005).","journal-title":"EMBO J."},{"key":"248_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/jacs.5b11807","volume":"138","author":"W Lee","year":"2016","unstructured":"Lee, W. et al. The mechanism of action of lysobactin. J. Am. Chem. Soc. 138, 100\u2013103 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"248_CR41","unstructured":"Abdrabou, A.M.M. Molecular Characterization of Clinical Clostridioides difficile Isolates Circulating in the German Healthcare System. Doctoral Thesis, Saarl\u00e4ndische Universit\u00e4ts- und Landesbibliothek (2022)."},{"key":"248_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1128\/IAI.05496-11","volume":"80","author":"CG Buffie","year":"2012","unstructured":"Buffie, C. G. et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80, 62\u201373 (2012).","journal-title":"Infect. Immun."},{"key":"248_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41586-022-04545-z","volume":"604","author":"X Cao","year":"2022","unstructured":"Cao, X. et al. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature 604, 541\u2013545 (2022).","journal-title":"Nature"},{"key":"248_CR44","doi-asserted-by":"publisher","first-page":"001857","DOI":"10.1099\/jmm.0.001857","volume":"73","author":"A Brosse","year":"2024","unstructured":"Brosse, A., Coullon, H., Janoir, C. & P\u00e9chin\u00e9, S. The state of play of rodent models for the study of Clostridioides difficile infection. J. Med. Microbiol. 73, 001857 (2024).","journal-title":"J. Med. Microbiol."},{"key":"248_CR45","unstructured":"CLSI M11-A8. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Eighth Edition https:\/\/webstore.ansi.org\/standards\/clsi\/CLSIM11A8 (2026)."},{"key":"248_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00121-25","volume":"63","author":"A Sobkowiak","year":"2025","unstructured":"Sobkowiak, A. et al. The dark matter of bacterial genomic surveillance-antimicrobial resistance plasmid transmissions in the hospital setting. J. Clin. Microbiol. 63, e0012125 (2025).","journal-title":"J. Clin. Microbiol."},{"key":"248_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4939-6361-4_9","volume":"1476","author":"AN Edwards","year":"2016","unstructured":"Edwards, A. N. & McBride, S. M. Isolating and purifying Clostridium difficile spores. Methods Mol. Biol. 1476, 117\u2013128 (2016).","journal-title":"Methods Mol. Biol."},{"key":"248_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2149019","volume":"14","author":"B Kircher","year":"2022","unstructured":"Kircher, B. et al. Predicting butyrate- and propionate-forming bacteria of gut microbiota from sequencing data. Gut Microbes 14, 2149019 (2022).","journal-title":"Gut Microbes"},{"key":"248_CR49","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581\u2013583 (2016).","journal-title":"Nat. Methods"}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00248-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:00:40Z","timestamp":1784714440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00248-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1038\/s44259-026-00248-x","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors disclose that R.M. is listed as an inventor on the patents WO 2010\/000601 A1 and US 9,217,169 B2, which cover the biosynthetic pathway enzymes and methods for the production of argyrins. These patents are not directly related to the experimental work or findings presented in this study, but are disclosed here in the interest of transparency. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"44"}}